Rubella Diagnostic Testing Market Size was valued at USD 1.4 Billion in 2023. The Rubella Diagnostic Testing Market industry is projected to grow from USD 1.47 Billion in 2024 to USD 2.16 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.60% during the forecast period (2024 - 2032). The advancements in testing procedures, reoccurrence of rubella outbreaks, and decreased number of vaccinations are expected to be significant market drivers for the Rubella Diagnostic Testing Market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for Rubella Diagnostic Testing is driven by the increasing incidences of rubella and the introduction of advanced point-of-care diagnostic technologies. The increasing prevalence of rubella is also fueling the need for higher diagnostics, thereby riding the growth of the studied market. For instance, in March 2022, the World Health Organization (WHO) mentioned that rubella is a main vaccine-preventable purpose of delivery defects. Similarly, an article posted in the Rubella Journal of Virology in April 2022 mentioned that rubella is an acute infection resulting from the rubella virus and characterized by fever and rash, with approximately 100,000 congenital rubella syndrome instances taking place within 12 months and stated globally. According to the Centers for Disease Control and Prevention, even though measles was declared removed within the United States in 2000, nearly 1,300 instances of measles had been mentioned in 31 states inside the U.S. In 2019, the most tremendously wide variety was considered to be 1992. According to facts, the World Health Organization said in early August 2023, India had the highest wide variety of measles instances compared to the relaxation of the world, with 57,550 instances as of 2023. Yemen with 24,596 and Pakistan with 10,549 sufferers.
The rubella diagnostic testing market is expanding due to the development of point-of-care diagnostics for rubella diagnosis. For instance, according to an article published in the book Advanced Materials in March 2022, recent research efforts have been made to implement fluorescent biosensors into the rapidly expanding field of point-of-care testing (POCT), which uses cost-effective strategies for rapid and affordable diagnostic testing for various diseases, including rubella. As a result, it is anticipated that throughout the projection period, demand for the Rubella Diagnostic Testing Market will increase due to increasing incidences of rubella and the introduction of advanced point-of-care diagnostic technologies. Thus, driving the Rubella Diagnostic Testing Market revenue.
The Rubella Diagnostic Testing Market segmentation, based on Testing Technique, includes Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA), Fluorescent Immunoassay (FIA), and Other Testing Techniques. The Enzyme Immunoassay (EIA) segment dominated the market, accounting for 58% of market revenue. The increasing provision of tests that are easy to apply and accurate is boosting the development of this sector. For instance, in July 2021, a mSphere published article reported that measles and rubella are a concern and can be prevented by vaccines (VPD); thus, measuring antibodies of these two viruses using serosurvey can help estimate the population immunity and guide immunization activities and enzyme immunoassay is the most expedient method to detect rubella virus.
The Rubella Diagnostic Testing Market segmentation, based on the Application, includes Hospitals, Laboratories, and Other Applications. The hospitals segment dominated the market, accounting for 58% of market revenue. Developments in laboratory diagnostic techniques have expanded RUBELLA screening availability and accuracy as well as reduced the cost of detection. Because hospitals are a larger investment market for medical technology, this investment becomes more attractive as a result, making diagnosing rubella in the hospital segment more readily achievable and thereby increasing the growth of the hospital segment within the Rubella Diagnostic Testing market.
Figure 1: Rubella Diagnostic Testing Market, by Application, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The anticipated expansion of the Rubella Diagnostic Testing market in North America can be attributed to several key factors. In January 2021, the CDC affirmed that the US has completed rubella chains of transmission, so transmissible illnesses such as rubella are no longer endemic in the US. As of 2004, rubella has been eradicated from the United States. Presently, according to the Centers for Disease Control, fewer than 10 rubella cases are reported in a year in the United States. On the other hand, according to the CDC, the primary strategy for the development of rubella-free regions here in America is to have a standard surveillance system. The best way to show how effective routine vaccination is that the region's government has put in is to combine it with exhaustive diagnostic campaigns that are conducted in countries with high case and death rates, which are the main public health strategies to reduce measles cases globally.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: RUBELLA DIAGNOSTIC TESTING MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Rubella Diagnostic Testing Market accounts for the second-largest market share as the growth of health spending in Europe has positively contributed to the implementation of diagnostic services and access to health care in general. In 2022, the total healthcare expenditure by EU governments was €1221 billion, or 7.7 GDP of the EU. Concerning the year 2022, the healthcare expenditure on 'hospital services' was 3.2% of GDP, for 'outpatient services' 2.3 % of GDP, 'medical products, apparatus, and appliances' was 1.1 %, and for 'public health services' it was 0.5 % of GDP. The portion of R&D towards health was an estimated contribution of 0.1 % of GDP. This enabled more people to have Rubella testing as it is now included as part of routine medical care but also if they had known reasons to have it, for example, because of their specific symptoms. Further, the German Rubella Diagnostic Testing Market held the largest market share, and the UK Rubella Diagnostic Testing Market was the fastest-growing market in the European region.
The Asia-Pacific Rubella Diagnostic Testing Market is expected to grow at the fastest CAGR from 2024 to 2032. Data from the CDC indicates that India is home to the highest number of cases from April to September 2022. The pandemic of WHA situation during the end of 2022 stood still in 7th position with a maximum of 3635 cases compared to 33 cases in the US. With the rise in measles cases last year, the government of India has proposed a treatment scheme to expand the diagnostic facilities developed for that. As an illustration, in July 2022, the Pradhan Mantri Surakshit Matritva Abhiyan Campaign by the Ministry of Health & Family Welfare (MoHFW), Government of India, undertaken to strengthen the quality and coverage of ANC with diagnostics and counseling services as part of the Reproductive Maternal Neonatal Child and Adolescent Health (RMNCH+A) strategy. Moreover, China’s Rubella Diagnostic Testing Market held the largest market share, and the Indian Rubella Diagnostic Testing Market was the fastest-growing market in the Asia-Pacific region.
Rubella Diagnostic Testing Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Rubella Diagnostic Testing market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Rubella Diagnostic Testing industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Rubella Diagnostic Testing industry to benefit clients and increase the market sector. In recent years, the Rubella Diagnostic Testing industry has offered some of the most significant advantages to the healthcare sector and public health efforts. Major players in the Rubella Diagnostic Testing Market, including Abbott Laboratories Inc., Beckman Coulter Inc., Bio Rad Laboratories Inc., Biokit SA, BioMérieux SA, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., ZEUS Scientific Inc are attempting to increase market demand by investing in research and development operations.
Abbott Laboratories is a company that performs research and creates, manufactures, and distributes a wide variety of healthcare products. Some of these products include adult and pediatric nutritional supplements, branded generic medicines, and diagnostic systems and tests. Heart failure, electrophysiology, rhythm management, vascular and structural heart devices, and neuromodulation devices are among the medical products that the company also offers. The company provides dietary supplements, nutrition products, and minerals. It operates manufacturing facilities all around the world and maintains research and development centers in the US, Colombia, India, Singapore, Spain, and the UK. The company sells its products across Europe, Asia-Pacific, Africa, Latin America, the Middle East, and North America. The US headquarters of Abbott is located in Abbott Park, Illinois.
Bio-Rad Laboratories Inc. (Bio-Rad) manufactures and distributes products for clinical diagnostics and life science research. Among the products offered by the company are antibodies, autoimmune testing kits, digital PCR, blood type and antibody detection systems, and devices for cell isolation and analysis. The company provides solutions to a variety of markets, such as analytical chemistry, healthcare, and life science research. Applications for Bio-Rad's products include immunology, gene expression analysis, cell research, bioprocess analytics, and mutation detection. It uses a network of international distributors, agents, brokers, and resellers in addition to a direct sales force to market its products. Among other nations, the company has operations in the US, Canada, Latin America, Europe, and Asia. The US company Bio-Rad Laboratories Inc. has its headquarters in Hercules, California.
Key companies in the Rubella Diagnostic Testing Market include
Rubella Diagnostic Testing Industry Developments
Feb 2023: To achieve the IA2030 measles and rubella-specific targets, the American Red Cross, United Nations Foundation, Centres for Disease Control and Prevention (CDC), Gavi, the Vaccines Alliance, the Bill and Melinda French Gates Foundation, UNICEF, and WHO developed the Immunization Agenda 2030 Measles & Rubella Partnership (M&RP) in 2023.
August 2022: Roche reported that the US Food and Drug Administration (USFDA) had approved an expansion of the label for its Ventana MMR RxDx Panel. This expansion provides doctors access to a fully automated panel of MMR biomarkers that are assessed by immunohistochemistry (IHC).
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.4 Billion |
| Market Size 2024 | USD 1.47 Billion |
| Market Size 2032 | USD 2.16 Billion |
| Compound Annual Growth Rate (CAGR) | 5.60% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Testing Technique, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott Laboratories Inc., Beckman Coulter Inc., Bio Rad Laboratories Inc., Biokit SA, BioMérieux SA, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., ZEUS Scientific Inc |
| Key Market Opportunities | · Innovation in diagnostic technologies for accuracy and accessibility. |
| Key Market Dynamics | · Essential for public health and disease control efforts. |
Frequently Asked Questions (FAQ) :
The Rubella Diagnostic Testing Market size was valued at USD 1.4 Billion in 2023.
The Rubella Diagnostic Testing Market is projected to grow at a CAGR of 5.60% during the forecast period 2024-2032.
North America had the largest share of the market.
The key players in the market are Abbott Laboratories Inc., Beckman Coulter Inc., Bio Rad Laboratories Inc., Biokit SA, BioMérieux SA, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., ZEUS Scientific Inc.
The Enzyme Immunoassay (EIA) segment dominated the market in 2023.
The Hospitals segment had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
